Zyentia Ltd
Based on technology developed by Professor Chris Dobson in the area of structural modification of proteins, Zyentia's initial focus was on the development of modified human calcitonin, a bone density regulator used in the treatment of osteoporosis.
Zyentia's protein aggregation prediction software was sold to Lonza in 2006, and the company is no longer trading.